Glenmark Pharmaceuticals Ltd management interview: Glenmark Eyes Strong H2 Recovery: CFO Anurag Mantri Explains What's Ahead
NDTV Profit, 2026-11-13. Video: https://www.youtube.com/watch?v=S8Jx0-RxZwY
- Revenue comparison: Reported revenue was down 30% year-on-year, reflecting ₹3,600 crore of AbbVie licensing income in the prior year; excluding licensing income, revenue was up 71%.
- Margin recovery: Excluding one-off items and licensing income, quarterly margin was 21%, almost 0.5% higher than the same quarter last year. H1 growth spending is expected to deliver operating leverage in H2, with management confident of meeting guidance for 21% to 22% EBITDA margins by FY27.
- North America growth: Core North America business grew 31% year-on-year, and management expects 25% to 30% growth this year. Monroe is cleared by the FDA, with products expected to contribute from FY28 onwards.
- Ryaltris outlook: The global franchise grew almost 40% in H1, with more than $130 million expected from the product this year and $300 million plus over the next 3 to 4 years. Glenmark has taken US marketing and sales in-house and expects further momentum in H2.
- Innovation pipeline: Glenmark plans to continue proprietary and partnered oncology innovation, targeting one molecule from its innovation lab entering clinics every year. Its 2301 penta-specific molecule targets solid tumors and is expected to be filed for an IND soon.